|
1
|
Meta-analysis Group in Cancer. Efficacy of
intravenous continuous infusion of fluorouracil compared with bolus
administration in advanced colorectal cancer. J Clin Oncol.
16:301–308. 1998.PubMed/NCBI
|
|
2
|
Saltz LB, Cox JV, Blanke C, et al:
Irinotecan plus fluorouracil and leucovorin for metastatic
colorectal cancer. Irinotecan Study Group. N Engl J Med.
343:905–914. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Douillard JY, Cunningham D, Roth AD, et
al: Irinotecan combined with fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic
colorectal cancer: a multicentre randomised trial. Lancet.
355:1041–1047. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
De Gramont A, Figer A, Seymour M, et al:
Leucovorin and fluorouracil with or without oxaliplatin as
first-line treatment in advanced colorectal cancer. J Clin Oncol.
18:2938–2947. 2000.
|
|
5
|
Giacchetti S, Perpoint B, Zidani R, et al:
Phase III multicenter randomized trial of oxaliplatin added to
chronomodulated fluorouracil-leucovorin as first-line treatment of
metastatic colorectal cancer. J Clin Oncol. 18:136–147. 2000.
|
|
6
|
Wagner JS, Adson MA and van Heerden JA:
The natural history of hepatic metastases from colorectal cancer: a
comparison with resective treatment. Ann Surg. 199:502–508. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Advanced Colorectal Cancer Meta-Analysis
Project. Modulation of fluorouracil by leucovorin in patients with
advanced colorectal cancer: evidence in terms of response rate.
Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol.
10:896–903. 1992.PubMed/NCBI
|
|
8
|
Thirion P, Michiels S, Pignon JP, et al:
Modulation of fluorouracil by leucovorin in patients with advanced
colorectal cancer: an updated meta-analysis. J Clin Oncol.
22:3766–3775. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hansen RM, Quebbeman E and Anderson T:
5-Fluorouracil by protracted venous infusion. A review of current
progress. Oncology. 46:245–250. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
DeGramont A, Bosset JF, Milan C, et al:
Randomized trial comparing monthly low-dose leucovorin and
fluorouracil bolus with bimonthly high-dose leucovorin and
fluorouracil bolus plus continuous infusion for advanced colorectal
cancer: a French intergroup study. J Clin Oncol. 15:808–815.
1997.
|
|
11
|
Goldberg RM, Sargent DJ, Morton RF, et al:
A randomized controlled trial of fluorouracil plus leucovorin,
irinotecan and oxaliplatin combinations in patients with previously
untreated metastatic colorectal cancer. J Clin Oncol. 22:23–30.
2004. View Article : Google Scholar
|
|
12
|
Kusunoki M, Yanagi H, Kotera H, Noda M and
Yamamura T: Effects of pharmacokinetic modulating chemotherapy
using oral UFT and continuous venous 5FU infusion on the prognosis
of irradiated rectal carcinomas with p53 overexpression. Int J
Oncol. 13:653–657. 1998.
|
|
13
|
Kusunoki M, Yanagi H, Noda M and Yamamura
T: The usefulness of pharmacokinetic modulating chemotherapy (UFT
plus 5FU) in the treatment of unresectable colorectal carcinomas.
Oncol Rep. 6:547–552. 1998.PubMed/NCBI
|
|
14
|
Kusunoki M, Yanagi H, Noda M, Yoshikawa R
and Yamamura T: Results of pharmacokinetic modulating chemotherapy
in combination with hepatic arterial 5-fluorouracil infusion and
oral UFT after resection of hepatic colorectal metastases. Cancer.
15:1228–1235. 2000. View Article : Google Scholar
|
|
15
|
Yoshikawa R, Kusunoki M, Yanagi H, et al:
Dual antitumor effects of 5-fluorouracil on the cell cycle in
colorectal carcinoma cells: a novel target mechanism concept for
pharmacokinetic modulating chemotherapy. Cancer Res. 1:1029–1037.
2001.
|
|
16
|
Kubota T, Fujita S, Kodaira S, et al:
Antitumor activity of fluoropyrimidines and thymidylate synthetase
inhibition. Jpn J Cancer Res. 82:476–482. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
NCI Common Toxicity Criteria Version 2.0.
Bethesda: National Cancer Institute, Division of Cancer Treatment;
1999
|
|
19
|
Aschele C, Sobrero A, Faderan MA and
Bertino JR: Novel mechanism(s) of resistance to 5-fluorouracil in
human colon cancer (HCT-8) sublines following exposure to two
different clinically relevant dose schedules. Cancer Res.
52:1855–1864. 1992.PubMed/NCBI
|
|
20
|
Sobrero AF, Aschele C, Guglielmi AP, et
al: Synergism and lack of cross-resistance between short-term and
continuous exposure to fluorouracil in human colon adenocarcinoma
cells. J Natl Cancer Inst. 85:1937–1944. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sobrero AF, Aschele C and Bertino JR:
Fluorouracil in colorectal cancer - a tale of two drugs:
implications for biochemical modulation. J Clin Oncol. 15:368–381.
1997.PubMed/NCBI
|
|
22
|
Fujii S, Ikenaka K, Fukushima M and
Shirasaka T: Effect of uracil and its derivatives on antitumor
activity of 5-fluorouracil and
1-(2-tetrahydrofuryl)-5-fluorouracil. Gann. 69:763–772.
1978.PubMed/NCBI
|
|
23
|
Fujii S, Kitano S, Ikenaka K and Shirasaka
T: Effect of co-administration of uracil or cytosine on the
anti-tumor activity of clinical doses of
1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in
rodents. Gann. 70:209–214. 1979.PubMed/NCBI
|
|
24
|
Inoue Y, Miki C, Hiro J, et al: Improved
survival using multi-modality therapy in patients with lung
metastases from colorectal cancer: A preliminary study. Oncol Rep.
14:1571–1576. 2005.PubMed/NCBI
|
|
25
|
Inoue Y, Toiyama Y, Tanaka K, Miki C and
Kusunoki M: A comprehensive comparative study on the
characteristics of colorectal cancer chemotherapy. Jpn J Clin
Oncol. 39:367–375. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gamelin E, Delva R, Jacob J, et al:
Individual fluorouracil dose adjustment based on pharmacokinetic
follow-up compared with conventional dosage: results of a
multicenter randomized trial of patients with metastatic colorectal
cancer. J Clin Oncol. 26:2099–2105. 2008. View Article : Google Scholar
|
|
27
|
Di Paolo A, Lencioni M, Amatori F, et al:
5-fluorouracil pharmacokinetics predicts disease-free survival in
patients administered adjuvant chemotherapy for colorectal cancer.
Clin Cancer Res. 14:2749–2755. 2008.PubMed/NCBI
|
